Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report
- 1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University
- 2Department of Pharmacy, Chongqing University Cancer Hospital
Abstract
Immune-mediated hepatotoxicity (IMH) is a typical immune-related adverse event associated with the use of immune checkpoint inhibitors (ICIs), while hepatitis B virus reactivation (HBVr) is an infectious complication that may also occur during ICI therapy. However, these two conditions are usually independent and rarely co-occur in the same individual. Herein, we describe a patient with lung squamous cell carcinoma who developed HBVr and IMH simultaneously after receiving tislelizumab, and the co-existence of two episodes of HBVr brings challenges to the diagnosis and treatment of IMH. In the diagnosis of IMH, the co-existence of HBVr masked the underlying IMH, resulting in a delay in IMH treatment. In the treatment of IMH, the re-occurrence of HBVr led to a dilemma of continuing to use glucocorticoids (GCs) or stopping them. In such a clinical scenario, the multidisciplinary approach, close monitoring of liver function and HBV-DNA, and a carefully balanced treatment strategy combining GCs with intensified antiviral therapy are essential to realize the optimal management for IMH. In conclusion, medical staff should be alert to the coexistence of HBVr and IMH in patients receiving ICIs, so as to avoid missed diagnosis and treatment delay.
Related
- Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
- [Comment] Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT- Ⅲ): a multicenter, randomized, openlabel, phase 3 trial
- Epinephrine-mediated sensitization of thioredoxin 1 enhances chlorpromazine protection against acute hepatotoxicity
- Beyond Steroids: Mycophenolate Mofetil Dosing in Immune Checkpoint Inhibitor-Mediated Hepatitis
- 977 An ICOS–IFN-γ T-cell signature links CNS immune-related adverse events and immune-mediated hepatitis following dual CTLA-4/PD-1 blockade
BibTeX
@article{li2026tislelizumabinduced,
title = {{Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report}},
author = {Dongxuan Li and Guiqin Peng},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1951692},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1951692/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tislelizumab-induced immune-mediated hepatotoxicity combined with two episodes of hepatitis B virus reactivation: a case report
AU - Dongxuan Li
AU - Guiqin Peng
PY - 2026
DA - 2026/10/13
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1951692
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1951692/full
AB - Immune-mediated hepatotoxicity (IMH) is a typical immune-related adverse event associated with the use of immune checkpoint inhibitors (ICIs), while hepatitis B virus reactivation (HBVr) is an infectious complication that may also occur during ICI therapy. However, these two conditions are usually independent and rarely co-occur in the same individual. Herein, we describe a patient with lung squamous cell carcinoma who developed HBVr and IMH simultaneously after receiving tislelizumab, and the co-existence of two episodes of HBVr brings challenges to the diagnosis and treatment of IMH. In the diagnosis of IMH, the co-existence of HBVr masked the underlying IMH, resulting in a delay in IMH treatment. In the treatment of IMH, the re-occurrence of HBVr led to a dilemma of continuing to use glucocorticoids (GCs) or stopping them. In such a clinical scenario, the multidisciplinary approach, close monitoring of liver function and HBV-DNA, and a carefully balanced treatment strategy combining GCs with intensified antiviral therapy are essential to realize the optimal management for IMH. In conclusion, medical staff should be alert to the coexistence of HBVr and IMH in patients receiving ICIs, so as to avoid missed diagnosis and treatment delay.
SN - 1663-9812
ER -